Duration of Marriage at Conception May Increase Schizophrenia Risk in Offspring
Offspring born to couples married for less than 3 years have a small increased risk for schizophrenia.
Schizophrenia
Long-Acting Atypical Antipsychotics Compared in Patients Experiencing an Acute Exacerbation of Schizophrenia
Results from the phase 3b ALPINE study, which evaluated Aristada (aripiprazole lauroxil; Alkermes) and Invega Sustenna (paliperidone palmitate; Janssen) in patients experiencing an acute exacerbation of schizophrenia, showed that both of these long-acting injectable treatments effectively controlled schizophrenia symptoms
Cognitive Behavioral Therapy for Insomnia Effective for Patients With Schizophrenia
Cognitive behavioral therapy shows promise promoting sleep in patients with schizophrenia.
Rykindo NDA for Schizophrenia, Bipolar Disorder Submitted to FDA
Luye Pharma Group announced the submission of a New Drug Application (NDA) for Rykindo (risperidone extended-release microsphere; LY03004) for Injectionto the Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar disorder.
Greater EEG Activity in Patients at High Risk for Psychosis Not Associated With Negative Symptoms
There may be no association between functioning and the slow wave power in the frontal region of individuals at ultra-high risk for psychosis.
Cognitive Control in Patients With Mental Illness Differs by Diagnosis
Study findings suggest a continuum of dysfunction in cognitive control across psychiatric illnesses, including bipolar and schizophrenia.
Aripiprazole Not Associated With Increased Hospitalizations, Suicidality in Patients Previously Treated With Antipsychotics
Introducing aripiprazole after previous antipsychotic exposure did not appear to increase serious psychiatric risk.
Depression Associated With Polygenic Risk for Major Depression, Bipolar Disorder, and Schizophrenia
Polygenic risk for major depression, bipolar, and schizophrenia is linked to depression in the general population.
Phone Contact Improved Medication Adherence in Severely Mentally Ill Patients
Telemedicine can deliver support to patients who are otherwise at high risk for progressive nonadherence to their psychotropic medication regimens.
Early Placebo Improvement May Be a Marker for Long-Term Placebo Response in Schizophrenia Trials
Investigators examine patients who demonstrated improvement after placebo injections and aimed to determine criteria to predict subsequent response.
Next post in Schizophrenia and Psychoses
